Literature DB >> 24842880

Current strategic thinking for the development of a trivalent alphavirus vaccine for human use.

Daniel N Wolfe1, D Gray Heppner2, Shea N Gardner2, Crystal Jaing2, Lesley C Dupuy2, Connie S Schmaljohn2, Kevin Carlton2.   

Abstract

Vaccinations against the encephalitic alphaviruses (western, eastern, and Venezuelan equine encephalitis virus) are of significant interest to biological defense, public health, and agricultural communities alike. Although vaccines licensed for veterinary applications are used in the Western Hemisphere and attenuated or inactivated viruses have been used under Investigational New Drug status to protect at-risk personnel, there are currently no licensed vaccines for use in humans. Here, we will discuss the need for a trivalent vaccine that can protect humans against all three viruses, recent progress to such a vaccine, and a strategy to continue development to Food and Drug Administration licensure. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24842880      PMCID: PMC4155543          DOI: 10.4269/ajtmh.14-0055

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  47 in total

1.  Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice.

Authors:  K A Bernard; W B Klimstra; R E Johnston
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

2.  Genetic and antigenic diversity among eastern equine encephalitis viruses from North, Central, and South America.

Authors:  A C Brault; A M Powers; C L Chavez; R N Lopez; M F Cachón; L F Gutierrez; W Kang; R B Tesh; R E Shope; S C Weaver
Journal:  Am J Trop Med Hyg       Date:  1999-10       Impact factor: 2.345

3.  Experimental infection of horses with enzootic and epizootic strains of Venezuelan equine encephalomyelitis virus.

Authors:  T E Walton; O Alvarez; R M Buckwalter; K M Johnson
Journal:  J Infect Dis       Date:  1973-09       Impact factor: 5.226

4.  Safety and efficacy of an attenuated Venezuelan equine encephalomyelitis vaccine for use in Equidae.

Authors:  R O Spertzel; D E Kahn
Journal:  J Am Vet Med Assoc       Date:  1971-09-15       Impact factor: 1.936

5.  Arbovirus isolations from mosquitoes collected during and after the 1982-1983 epizootic of western equine encephalitis in Argentina.

Authors:  C J Mitchell; T P Monath; M S Sabattini; J F Daffner; C B Cropp; C H Calisher; R F Darsie; W L Jakob
Journal:  Am J Trop Med Hyg       Date:  1987-01       Impact factor: 2.345

6.  Positively charged amino acid substitutions in the e2 envelope glycoprotein are associated with the emergence of venezuelan equine encephalitis virus.

Authors:  Aaron C Brault; Ann M Powers; Edward C Holmes; C H Woelk; Scott C Weaver
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.

Authors:  P Pushko; M Bray; G V Ludwig; M Parker; A Schmaljohn; A Sanchez; P B Jahrling; J F Smith
Journal:  Vaccine       Date:  2000-08-15       Impact factor: 3.641

8.  Experimental infection of horses with an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83).

Authors:  T E Walton; O Alvarez; R M Buckwalter; K M Johnson
Journal:  Infect Immun       Date:  1972-05       Impact factor: 3.441

9.  Reevaluation of the western equine encephalitis antigenic complex of alphaviruses (family Togaviridae) as determined by neutralization tests.

Authors:  C H Calisher; N Karabatsos; J S Lazuick; T P Monath; K L Wolff
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

10.  SNP-associations and phenotype predictions from hundreds of microbial genomes without genome alignments.

Authors:  Barry G Hall
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more
  6 in total

1.  Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.

Authors:  Emily E Coates; Srilatha Edupuganti; Grace L Chen; Myra Happe; Larisa Strom; Alicia Widge; Maria Burgos Florez; Josephine H Cox; Ingelise Gordon; Sarah Plummer; Abidemi Ola; Galina Yamshchikov; Charla Andrews; Sharon Curate-Ingram; Patricia Morgan; Shashi Nagar; Matthew H Collins; Amy Bray; Thuy Nguyen; Judy Stein; Christopher L Case; Florence Kaltovich; Diane Wycuff; C Jason Liang; Kevin Carlton; Sandra Vazquez; John R Mascola; Julie E Ledgerwood
Journal:  Lancet Infect Dis       Date:  2022-05-11       Impact factor: 71.421

2.  Comparison of Aerosol- and Percutaneous-acquired Venezuelan Equine Encephalitis in Humans and Nonhuman Primates for Suitability in Predicting Clinical Efficacy under the Animal Rule.

Authors:  Janice M Rusnak; Lesley C Dupuy; Nancy A Niemuth; Andrew M Glenn; Lucy A Ward
Journal:  Comp Med       Date:  2018-10-03       Impact factor: 0.982

3.  Designing multivalent immunogens for alphavirus vaccine optimization.

Authors:  C M Read; Kenneth Plante; Grace Rafael; Shannan L Rossi; Werner Braun; Scott C Weaver; Catherine H Schein
Journal:  Virology       Date:  2021-02-05       Impact factor: 3.513

4.  Characterization of Genetic Variability of Venezuelan Equine Encephalitis Viruses.

Authors:  Shea N Gardner; Kevin McLoughlin; Nicholas A Be; Jonathan Allen; Scott C Weaver; Naomi Forrester; Mathilde Guerbois; Crystal Jaing
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

5.  Characterization and pathogenesis of aerosolized eastern equine encephalitis in the common marmoset (Callithrix jacchus).

Authors:  Aimee I Porter; Rebecca A Erwin-Cohen; Nancy Twenhafel; Taylor Chance; Steven B Yee; Steven J Kern; David Norwood; Laurie J Hartman; Michael D Parker; Pamela J Glass; Luis DaSilva
Journal:  Virol J       Date:  2017-02-07       Impact factor: 4.099

6.  A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges.

Authors:  Lesley C Dupuy; Michelle J Richards; Brian D Livingston; Drew Hannaman; Connie S Schmaljohn
Journal:  J Immunol Res       Date:  2018-06-03       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.